Futura Medical plc (FUM) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to the Futura Medical PLC Infant Results Investor Presentation. Throughout this quarter's presentation, investors will be in listen-only mode. Questions are encouraged and can be submitted at any time by the Q&A tab situated in the right corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all the questions submitted today and publish responses where it is appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand it to James Barter, CEO. Good morning, sir. Good morning, everyone, and welcome to Futura Medical's interim results presentation for the period ending 30 June 2024. I am James Varda, CEO of Futura, and I'm joined today by Angela Hildreth, Futura's finance director and CEO, and also Ken James, executive director and Futura's head of R&D. Futura specializes in the development and commercialization of innovative sexual health care products across the board. Our lead product is a Roxxon a clinically proven breakthrough treatment for erectile dysfunction. Our key area of expertise is in topically delivered gel formulation. Next slide. Hi, everyone. This is Ken James. Having worked my career in consumer healthcare, I can say that it is rare to have a product such as a Roxxon, which is truly unique, as it is a breakthrough, safe and effective treatment for erectile dysfunction. Why is it a breakthrough? Because of its excellent safety profile, it's available without a doctor's prescription or pharmacy consultation. This is in contrast to the oral medications known as PDE5 inhibitors, such as Viagra and Cialis, which are only available on prescription in ...